Sanofi pays $315M to settle claims it delayed Lemtrada to avoid investor payouts
admin 4th November 2019 Uncategorised 0When Sanofi bought Genzyme in 2011, Lemtrada was only a promising multiple sclerosis drug candidate, so the French drugmaker promised the biotech’s shareholders future payments if the med hit particular goals. Years later, those investors claimed Sanofi dragged its feet
read more